Summary

Birth order and bad second languages and Bolivia. In this episode of Melanoma Matters, hosts Sapna Patel and James Larkin discuss the Checkmate 915 trial, a significant study in the adjuvant treatment of melanoma. They explore the trial's design, the implications of IPI dosing, and the balance between efficacy and toxicity. The conversation emphasizes the importance of understanding negative studies in clinical research and the need for careful consideration in trial design, particularly in the adjuvant setting.

Keywords

Checkmate 915, melanoma, adjuvant therapy, IPI dosing, trial design, toxicity, efficacy, negative studies, immunotherapy, clinical trials

Takeaways

Checkmate 915 was a large adjuvant trial in melanoma.

The trial compared Nivolumab monotherapy to Nivolumab with low-dose IPI.

There was no improvement in relapse-free survival with the addition of IPI.

Toxicity was higher in the IPI-containing arm, as expected.

The dosing of IPI in Checkmate 915 was significantly lower than in metastatic settings.

Understanding the trade-off between efficacy and toxicity is crucial in adjuvant therapy.

Negative studies are important for learning and future trial designs.

The design of Checkmate 915 was pragmatic given the context of adjuvant treatment.

Future research may benefit from exploring neoadjuvant models.

The conversation highlights the need for more discussions on negative trials.

Titles

Checkmate 915: What Went Wrong?

Understanding Checkmate 915: A Deep Dive

Sound Bites

"This was an important large study in our field."

"The addition of this low dose IPI regimen did not improve relapse free survival."

"We need to try and think more and talk more about why studies are negative."

Chapters

00:00 Introduction and Quick Fire Questions

02:50 Discussion of Checkmate 915 Study

11:02 The Dosing Dilemma: Ipilimumab in the Adjuvant Setting

15:41 Takeaways from Checkmate 915 Study